Degenerative disc disease (DDD) is a condition where spinal discs lose flexibility and height, causing pain and reduced mobility. It accounts for around 30% of people aged 30-50 years experiencing some degree of disc degeneration. There is a growing focus on developing advanced drug candidates to address pain and restore disc function. Recent advancements include regenerative medicine and biologics, which are expected to drive market growth. Moreover, the increasing prevalence of the condition and the rising demand for innovative degenerative disc disease therapeutic products are anticipated to fuel market expansion in the coming years.
Major companies involved in the degenerative disc disease pipeline drugs market include Angitia Biopharmaceuticals, Spine BioPharma, Inc., and others.
Leading drugs currently in the pipeline include AGA111, CELZ-201-DDT, TG-C, and others.
Advancements in regenerative medicine and targeted biologics, coupled with robust clinical research initiatives, are driving the growth of the degenerative disc disease drug pipeline.
The Degenerative Disc Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into degenerative disc disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for degenerative disc disease. The degenerative disc disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The degenerative disc disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with degenerative disc disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to degenerative disc disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Degenerative disc disease (DDD) is a condition characterized by the gradual deterioration of spinal discs over time, resulting in pain and reduced flexibility. This degeneration occurs as the discs lose hydration and elasticity, which decreases their ability to cushion the vertebrae. Factors contributing to this process include aging, repetitive stress, and injuries.
Management of degenerative disc disease involves various treatments. Physical therapy helps strengthen the muscles that support the spine, thereby improving stability. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) can help alleviate pain and inflammation. In more severe cases, surgical options like spinal fusion or artificial disc replacement may be considered to restore function and relieve discomfort.
Degenerative disc disease is a common condition affecting at least 30% of individuals aged 30 to 50 years. The highest estimated incidence is in Europe at 5.7 percent, with 5,668 cases per 100,000 people. In Japan, over one million people are affected annually, with approximately 200,000 requiring surgical intervention. Ongoing research is focusing on innovative therapies to address this growing healthcare challenge.
This section of the report covers the analysis of degenerative disc disease drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total degenerative disc disease clinical trials.
The drug molecule categories covered under the degenerative disc disease pipeline analysis include small molecules, biologics, cell-based therapies, monoclonal antibodies, and others. The degenerative disc disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for degenerative disc disease.
The EMR report for the degenerative disc disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed degenerative disc disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in degenerative disc disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for degenerative disc disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of degenerative disc disease drug candidates.
AGA111, developed by Angitia Biopharmaceuticals, is indicated for degenerative disc disease. Currently in a Phase III clinical trial, it is being studied for its efficacy and safety following a single local injection into the intervertebral space in patients undergoing lumbar interbody fusion. The drug works by targeting specific signaling pathways to enhance spinal fusion and improve patient outcomes.
CELZ-201-DDT, sponsored by Creative Medical Technology Holdings Inc., is currently in a Phase II clinical trial. The study is focused on evaluating the safety, tolerability, and efficacy of CELZ-201-DDT for treating chronic lower back pain caused by degenerative disc disease. This investigational drug uses AlloStem, an allogeneic perinatal cell-based therapy, aiming to repair tissues and improve blood supply through ultrasound-guided intramuscular injections.
TG-C is an allogeneic cell and gene therapy developed by Kolon TissueGene, Inc. It combines primary human chondrocytes with cells engineered to express TGF-β1, aiming to treat degenerative disc disease. It is a part of a Phase I study, which is evaluating the safety and tolerability of TG-C in subjects with chronic discogenic lumbar back pain due to degenerative disc disease.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Degenerative Disc Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for degenerative disc disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into degenerative disc disease collaborations, regulatory environments, and potential growth opportunities.
Spinal Cord Injury Market Report and Forecast
Global Spinal Implants and Surgery Devices Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share